Insights into the Efficacy of CT-P13, A Biosimilar of Infliximab, in Patients with IBS

Synopsis CT-P13, which is a biosimilar of infliximab, has recently been shown to be equivalent to infliximab in both efficacy and safety in the treatment of irritable bowel syndrome (IBS). The present study highlights the efficacy and safety of CT-P13 in IBS patients. This week’s “ MED FACT ” d iscusses a clinical trial from Journal of Gastroenterology and Hepatology , “ Studies on the efficacy of CT-P13, A Biosimilar of Infliximab, in Patients with IBS ”. Authors : Yoon Suk Jung, Dong Il Park, Young Ho Kim, Ji Hyun Lee, Pyoung Ju Seo, Jae Hee Cheon, Hyoun Woo Kang, and Ji Won Kim.

Key Takeaways: Objective : Analyzing the pharmacologic safety and efficacy of CT-P13 in IBS patients. Study Type: Retrospective multicenter study Participants : 110 What was the need for this study? CT-P13 is the world’s first biosimilar monoclonal antibody to the generic drug infliximab. It is prepared using the…